Tuesday, 18 Jun 2019

You are here

Steroids, Not Biologics, Drive Arthroplasty Infections in RA

Medicare and Truven MarketScan administrative data study (2006 through 2015) of rheumatoid arthritis (RA) undergoing arthroplasty found that while that the risks of perioperative infection was similar across biologics, the infection risk with glucocorticoid use, especially at > 10 mg/d, was significantly greater.

Retrospective analysis of RA patients having elective knee or hip arthroplasty, looked at the influence of recently infused biologic therapies, including abatacept, adalimumab, etanercept, infliximab, rituximab, or tocilizumab.

A total of 9911 biologic-treated patients had 10,923 surgical procedures were identified.

The risk of hospitalized infection did not vary significanly with biologic use and ranged from:

  • 6.87% with adalimumab
  • 8.16% with abatacept
  • 8.90% with rituximab C

The 1 year prosthetic joint infection (PJI) rates were:

  • 2.14% with abatacept
  • 0.35% with rituximab
  • 3.67% with tocilizumab.

However glucocorticoids were associated with a dose-dependent increase in postoperative risk for all outcomes, including hospitalized infection (13.25%;CI, 9.72% to 17.81%) (vs. 6.78% on no steroids) and a predicted 1-year cumulative incidence of PJI of 3.83% (CI, 2.13% to 6.87%) (vs. 2.09%).



The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Management of Hemophagocytic Lymphohistiocytosis (HLH) in Adults

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by activated macrophages and cytotoxic T cells.  HLH manifests recurrent fever, cytopenia, liver dysfunction, and a sepsis-like syndrome that may complicated by multiple organ failure.

More Trouble for Mallinckrodt’s Acthar Gel

Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.

FDA Public Review of CBD Oil

The US Food and Drug Administration convened a public hearing and specialty panel on May 31st to review the potential use, safety and effectiveness of cannabidiol (CBD) products that do not contain THC.

In his opening remarks, the FDA acting Commissioner Dr. Ned Sharpless said, "critical questions remain about the safety" of CBD products, especially since the growth of the CBD market has exploded in the past year.

Generic Price Fixing Alleged by State Prosecutors

The NY Times and 60 Minutes have reported that Connecticut, along with 43 other states, filed a mega-lawsuit accusing the generic drug makers of a massive, systematic conspiracy to bilk consumers out of billions of dollars. (Citation source: https://buff.ly/2vSmv03)

Drug Pricing Regulations in US and Canada

Reuters reports on regulatory efforts by Canada and the US to curb the rising cost of drugs, especially expensive new medicines. 

In Canada, a little-known government agency is increasing its oversight of expensive drugs sold in Canada. The federal Patented Medicine Prices Review Board (PMPRB) is targeting an increasing number of expensive drugs introduced in the last several years by drug makers.